

PATIENT INFORMATION

Date:	Patient Name:	Last 4 SSN	DOB:
Address:	City:	ST:	Zip:
Primary Phone:		Work Phone:	
Gender: M F	Weight lbs/kg:	Height:	Allergies:
Primary Insurance:		Secondary Insurance:	
Member#:	Group#:	Member#:	Group#:

Diagnosis: _____

Documentation needed: Insurance cards Most recent clinical including H&P Labs Diagnostic testing results

Medication	Order
Actemra - IV	<input type="checkbox"/> 4 mg/kg Freq: <input type="checkbox"/> Every 2 weeks <input type="checkbox"/> 8 mg/kg <input type="checkbox"/> Every 4 weeks <input type="checkbox"/> 6 mg/kg <input type="checkbox"/> Every ___ weeks <input type="checkbox"/> 10 mg/kg <input type="checkbox"/> 12 mg/kg <input type="checkbox"/> Other:
Actemra - Subcutaneous	<input type="checkbox"/> 162 mg sub-Q Freq: <input type="checkbox"/> Every week <input type="checkbox"/> Every 2 weeks <input type="checkbox"/> Every ___ weeks
Benlysta - IV	<input type="checkbox"/> Initial: 10 mg/kg IV every 2 weeks for 3 doses, then maintenance <input type="checkbox"/> Maintenance: 10 mg/kg every 4 weeks <input type="checkbox"/> Other:
Benlysta - Subcutaneous	<input type="checkbox"/> 200 mg sub-Q once weekly <input type="checkbox"/> 400 mg sub-Q once weekly x 4 doses, then 200 mg weekly
Cimzia – Subcutaneous or IV (suite only)	<input type="checkbox"/> Initial: 400 mg week 0, week 2, week 4, then maintenance <input type="checkbox"/> Maintenance: 400 mg every 2 weeks <input type="checkbox"/> Other: <input type="checkbox"/> Sub-Q <input type="checkbox"/> IV (Suite Only)
Enbrel - Subcutaneous	<input type="checkbox"/> 50 mg sub-Q ___ weekly <input type="checkbox"/> Other:
Forteo - Subcutaneous	<input type="checkbox"/> Inject 20 mcg Sub-Q daily <input type="checkbox"/> Other:
Humira - Subcutaneous	<input type="checkbox"/> 40 mg sub-Q every other week <input type="checkbox"/> Other:
Infliximab - IV <input type="checkbox"/> Remicade <input type="checkbox"/> Inflectra <input type="checkbox"/> Renflexis	<input type="checkbox"/> 3 mg/kg Freq: <input type="checkbox"/> Initial: week 0, week 2, week 6, then maintenance <input type="checkbox"/> 5 mg/kg <input type="checkbox"/> Maintenance: <input type="checkbox"/> Every 6 weeks <input type="checkbox"/> 8 weeks <input type="checkbox"/> _____ weeks <input type="checkbox"/> _____ mg/kg <input type="checkbox"/> _____ mg
Krystexxa - IV	<input type="checkbox"/> 8 mg every 2 weeks

Orencia - IV	<input type="checkbox"/> 500 mg Freq: <input type="checkbox"/> Initial: week 0, week 2, week 4, then maintenance <input type="checkbox"/> 750 mg <input type="checkbox"/> Maintenance: Every 4 weeks <input type="checkbox"/> 1,000 mg <input type="checkbox"/> Other: <input type="checkbox"/> Other:
Orencia - Subcutaneous	<input type="checkbox"/> 125 mg Sub-Q every week
Prolia - Subcutaneous	<input type="checkbox"/> 60 mg sub-Q every 6 months <input type="checkbox"/> Other:
Reclast - IV	<input type="checkbox"/> 5 mg every 12 months
Rituximab - IV <input type="checkbox"/> Rituxan <input type="checkbox"/> Truxima <input type="checkbox"/> Ruxience	<input type="checkbox"/> Initial: 1000 mg day 1 and day 15, then maintenance <input type="checkbox"/> Repeat course every 6 months <input type="checkbox"/> Other:
Simponi Aria - IV	<input type="checkbox"/> Initial: 2 mg/kg week 0 and 4, then maintenance <input type="checkbox"/> Other: <input type="checkbox"/> Maintenance: Every 8 weeks <input type="checkbox"/> Other:
Simponi - Subcutaneous	<input type="checkbox"/> 50 mg sub-Q every 4 weeks <input type="checkbox"/> Other:
Skyrizi - Subcutaneous	<input type="checkbox"/> Initial: 150 mg sub-Q week 0 and week 4, then maintenance <input type="checkbox"/> Maintenance: 150 mg sub-Q every 12 weeks
Stelara - Subcutaneous	<input type="checkbox"/> Initial: 45 mg week 0 and week 4, then maintenance <input type="checkbox"/> Initial: 90 mg week 0 and week 4, then maintenance <input type="checkbox"/> Maintenance: every 12 weeks <input type="checkbox"/> Other:
Tremfya - Subcutaneous	<input type="checkbox"/> Initial: 100 mg sub-Q week 0 and week 4, then maintenance <input type="checkbox"/> Maintenance: 100 mg sub-Q every 8 weeks
Xeljanz - Oral	<input type="checkbox"/> 5 mg PO twice daily <input type="checkbox"/> 11 mg XR PO once daily <input type="checkbox"/> Other:

Nursing

- Establish and/or maintain access device as needed for dose administration
- Administer by ordered route
- Obtain vital signs prior to, throughout as directed and at completion of infusion
- If reaction occurs follow procedure reaction management

PROVIDER INFORMATION

By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. Axiva Health Solutions, Inc., has my permission to contact the patient's health plan to obtain authorizations necessary to enable it to receive payment for services.

Physician Name:	NPI:	DEA:	License:
Address:	City:	ST:	Zip:
Phone:	Fax:	Office Contact:	

Physician Signature Required – Substitution Permitted Date

Physician Signature Required – Dispense as Written Date